New Mexico Clinical Trials Report — March 2026

Immediate Enrollment Deadlines Approaching

Time is strictly limited for New Mexico residents looking to participate in several active medical research programs. Over the next ninety days, 21 clinical trials will permanently close their enrollment windows across the state. This impending deadline creates a narrow window for patients seeking access to experimental therapies, behavioral interventions, and specialized medical procedures before these studies transition to the data analysis phase. Among these concluding studies, researchers are actively seeking to fill the final open spots for individuals managing specific acute and chronic diagnoses. Final enrollment phases are approaching quickly for studies focused on the following conditions and procedures:

• Endometrial carcinomas and clear cell adenocarcinomas
• Atopic dermatitis
• Chronic kidney disease requiring dialysis
• Developmental delay
• Atrial fibrillation
• Dilation and evacuation procedures

While the majority of these concluding studies require participants to have a specific medical history or current diagnosis, individuals without underlying health conditions still have a brief opportunity to contribute to medical science. Currently, 2 of the trials closing within the next ninety days are actively accepting healthy volunteers. These participants are crucial for finalizing control group data before the research windows permanently close.

Academic Device Research and March Additions

March brings a highly specialized focus to New Mexico's research landscape, with 2 new clinical trials launching this month. This represents a slight deceleration from the steady pace of five new studies opened in both January and February. Looking back at the broader six-month trend, the state's research activity has experienced distinct fluctuations. Following a quiet period last September with just a single new trial, momentum built rapidly through the fall, culminating in a robust sixteen new studies in December. The pace stabilized throughout the early winter before arriving at the current highly targeted March landscape.

While this month does not feature massive late-stage pharmaceutical trials from major industry sponsors, the newly opened studies highlight the critical role of academic institutions in advancing medical technology. Both of the new studies launched in March are categorized as device trials rather than drug interventions. Device trials are essential for evaluating the safety, efficacy, and real-world application of new medical instruments, surgical tools, and diagnostic equipment.

The University of New Mexico and the University of Nevada, Reno are the primary sponsors driving this month's localized research efforts. Their clinical teams are actively recruiting patients to evaluate new procedural approaches and hardware for specific medical situations. Researchers are currently seeking participants for studies addressing:

• Intratracheal intubation procedures
• Rotator cuff tear repairs and recovery

Statewide Access and Regional Research Hubs

Despite the lighter volume of new trial launches this month, New Mexico maintains a robust and highly accessible clinical research infrastructure. There are currently 386 active clinical trials recruiting participants across the state. These studies are distributed throughout 13 different cities, utilizing 204 distinct research sites. This geographic spread ensures that advanced medical care and experimental treatments are not entirely confined to a single metropolitan area.

This month's new research opportunities reflect this balance between central medical hubs and regional community access. Albuquerque continues to serve as the primary medical epicenter for the state, hosting one of the newly launched device trials. This concentration in the state's largest city provides a dense network of specialized care and advanced research facilities for complex procedures. However, the second trial launched this month has opened its doors in Taos, demonstrating an ongoing commitment to bringing clinical research opportunities to communities outside the immediate central metropolitan corridor. Patients living in rural or suburban areas often face logistical hurdles when seeking experimental treatments, making the activation of sites in regional municipalities a vital step toward equitable healthcare access.

Participant Eligibility and Demographic Focus

Eligibility criteria for March's newly launched studies are designed to accommodate adult populations, with a particular emphasis on ensuring older demographics can participate in orthopedic and airway management advancements. Both of the new device trials have structured their protocols to explicitly include older adults, ensuring that medical devices are tested on the populations that frequently require them. Neither of the studies launched this month restrict participation exclusively to male or female patients, and neither is currently open to pediatric populations.

For individuals without a specific medical diagnosis who wish to advance clinical science, the broader state landscape offers numerous avenues for participation. While neither of the two new trials launched this month is equipped to accept healthy volunteers, the state maintains a strong baseline of opportunities for those without underlying conditions. There are currently 38 active trials recruiting healthy volunteers statewide. These participants remain essential for establishing baseline health metrics, testing diagnostic equipment, and serving as control groups for broader therapeutic studies.

As the spring research season progresses, New Mexico's clinical trial ecosystem is positioned to expand its focus on localized academic partnerships, with regional medical centers likely driving the next wave of specialized orthopedic and respiratory device innovations.